Right Ventricular Metrics as End Points in Clinical Trials

RV-specific end points hold substantial promise for enhancing the sensitivity and mechanistic insight of clinical trials but remain inadequately integrated into current practice. Optimal end-point selection requires balancing clinical relevance, analytical validity, and operational feasibility, with consideration of disease-specific pathophysiology and trial design. Standardization of acquisition, validation of clinically meaningful changes, and centralized data analysis are important next steps. Broader adoption of robust RV metrics supported by technological innovation and cross-sector collaboration has the potential to improve trial efficiency, accelerate therapeutic development, and ultimately enhance patient outcomes.

Corresponding Authors: Elena Surkova, MD, PhD, MSc, Translational Science and Clinical Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals Relena.surkova.md@gmail.com&D, AstraZeneca, The Discovery Centre, Cambridge Biomedical Campus, 1 Francis Crick Ave, Cambridge CB2 0AA, United Kingdom (attila.kovacs@semmelweis.hu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.